KR101831123B1 - 세포내 항원에 대해 지향된 단일 도메인 항체 - Google Patents

세포내 항원에 대해 지향된 단일 도메인 항체 Download PDF

Info

Publication number
KR101831123B1
KR101831123B1 KR1020177006630A KR20177006630A KR101831123B1 KR 101831123 B1 KR101831123 B1 KR 101831123B1 KR 1020177006630 A KR1020177006630 A KR 1020177006630A KR 20177006630 A KR20177006630 A KR 20177006630A KR 101831123 B1 KR101831123 B1 KR 101831123B1
Authority
KR
South Korea
Prior art keywords
stat3
sdab
seq
vhh13
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177006630A
Other languages
English (en)
Korean (ko)
Other versions
KR20170070002A (ko
Inventor
수난다 싱
Original Assignee
싱 바이오테크놀로지, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 싱 바이오테크놀로지, 엘엘씨 filed Critical 싱 바이오테크놀로지, 엘엘씨
Publication of KR20170070002A publication Critical patent/KR20170070002A/ko
Application granted granted Critical
Publication of KR101831123B1 publication Critical patent/KR101831123B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
KR1020177006630A 2014-10-23 2015-10-23 세포내 항원에 대해 지향된 단일 도메인 항체 Active KR101831123B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462067908P 2014-10-23 2014-10-23
US62/067,908 2014-10-23
US201562148656P 2015-04-16 2015-04-16
US62/148,656 2015-04-16
US201562188353P 2015-07-02 2015-07-02
US62/188,353 2015-07-02
US201562210795P 2015-08-27 2015-08-27
US62/210,795 2015-08-27
PCT/US2015/057223 WO2016065323A2 (en) 2014-10-23 2015-10-23 Single domain antibodies directed against intracellular antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187004337A Division KR102023289B1 (ko) 2014-10-23 2015-10-23 세포내 항원에 대해 지향된 단일 도메인 항체

Publications (2)

Publication Number Publication Date
KR20170070002A KR20170070002A (ko) 2017-06-21
KR101831123B1 true KR101831123B1 (ko) 2018-02-22

Family

ID=55761757

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020177006630A Active KR101831123B1 (ko) 2014-10-23 2015-10-23 세포내 항원에 대해 지향된 단일 도메인 항체
KR1020197026711A Active KR102207382B1 (ko) 2014-10-23 2015-10-23 세포내 항원에 대해 지향된 단일 도메인 항체
KR1020197026708A Active KR102207381B1 (ko) 2014-10-23 2015-10-23 세포내 항원에 대해 지향된 단일 도메인 항체
KR1020187004337A Active KR102023289B1 (ko) 2014-10-23 2015-10-23 세포내 항원에 대해 지향된 단일 도메인 항체

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020197026711A Active KR102207382B1 (ko) 2014-10-23 2015-10-23 세포내 항원에 대해 지향된 단일 도메인 항체
KR1020197026708A Active KR102207381B1 (ko) 2014-10-23 2015-10-23 세포내 항원에 대해 지향된 단일 도메인 항체
KR1020187004337A Active KR102023289B1 (ko) 2014-10-23 2015-10-23 세포내 항원에 대해 지향된 단일 도메인 항체

Country Status (24)

Country Link
US (4) US9546211B2 (enExample)
EP (3) EP3590962B1 (enExample)
JP (5) JP2017538671A (enExample)
KR (4) KR101831123B1 (enExample)
CN (2) CN106852148B (enExample)
AU (4) AU2015335600B2 (enExample)
BR (4) BR122020006918B8 (enExample)
CA (3) CA3052777C (enExample)
CY (2) CY1122035T1 (enExample)
DK (2) DK3209685T3 (enExample)
ES (2) ES2900253T3 (enExample)
HR (2) HRP20191056T1 (enExample)
HU (2) HUE047601T2 (enExample)
IL (2) IL289769B2 (enExample)
LT (2) LT3590962T (enExample)
MX (2) MX379450B (enExample)
PL (2) PL3590962T3 (enExample)
PT (2) PT3209685T (enExample)
RS (2) RS62694B1 (enExample)
RU (1) RU2017116710A (enExample)
SI (2) SI3209685T1 (enExample)
SM (2) SMT202100695T1 (enExample)
TW (1) TWI664289B (enExample)
WO (1) WO2016065323A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170267784A1 (en) * 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
HUE047601T2 (hu) 2014-10-23 2020-05-28 Singh Molecular Medicine Llc Intracelluláris antigének ellen irányuló egyetlen domén antitestek
US20180072815A1 (en) 2014-10-23 2018-03-15 Singh Biotechnology, Llc Single Domain Antibodies Directed Against Intracellular Antigens
JP2018511346A (ja) 2015-03-31 2018-04-26 ブイエイチスクエアード リミテッド ポリペプチド
WO2016156466A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker
CA3255406A1 (en) 2015-03-31 2025-07-03 Sorriso Pharmaceuticals, Inc. Tnf-alpha binding polypeptides
BR112018004069A2 (pt) 2015-09-01 2021-07-13 First Wave Bio, Inc. composição farmacêutica sólida, preparação de enema compreendendo niclosamida, formulação de enema, uso de niclosamida e kit
TWI746473B (zh) 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
CN112274649A (zh) * 2015-12-10 2021-01-29 希望之城 细胞穿透花青偶联抗体
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
CN111010866A (zh) 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
KR20190076354A (ko) * 2017-12-22 2019-07-02 주식회사 로피바이오 세포 내 침투능을 갖는 항 stat3 이중특이 항체를 포함하는, 염증성 질환 치료용 약학적 조성물
CN111699002B (zh) 2017-12-22 2024-06-28 罗菲佰欧株式会社 抗stat3双特异性抗体及包含其的药学组合物
JP2021523115A (ja) * 2018-05-04 2021-09-02 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 炎症性疾患または障害を治療するための方法および組成物
KR102101561B1 (ko) * 2018-07-25 2020-04-20 가톨릭대학교 산학협력단 신생혈관 표적용 조영제 조성물 및 이의 제조방법
US11739146B2 (en) 2019-05-20 2023-08-29 Pandion Operations, Inc. MAdCAM targeted immunotolerance
CN114466864B (zh) 2019-06-21 2024-12-27 索瑞索制药公司 多肽
JP7680377B2 (ja) 2019-06-21 2025-05-20 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
CN110357965A (zh) * 2019-06-24 2019-10-22 浙江大学 一种突变型kras特异性抗体及其制备方法
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CN115485289A (zh) 2020-03-11 2022-12-16 宾夕法尼亚大学董事会 使用工程化的病毒颗粒进行基因递送的方法和组合物
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
CN115215939B (zh) * 2021-04-14 2025-09-23 中山大学 一种融合蛋白及其制备方法与应用
WO2023283381A1 (en) * 2021-07-07 2023-01-12 Singh Biotechnology, Llc Suppression of uveitis by single domain antibody
US20240101652A1 (en) * 2021-08-27 2024-03-28 Singh Biotechnology, Llc Therapeutic single domain antibody
CA3239267A1 (en) 2021-12-15 2023-06-22 Ronnie M. RUSSELL Pseudotyped viral particles, compositions comprising the same, and uses thereof
WO2024003873A1 (en) * 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha
IL317811A (en) 2022-07-25 2025-02-01 Interius Biotherapeutics Inc Mutated polypeptides, compositions containing them and uses thereof
WO2024163894A1 (en) 2023-02-04 2024-08-08 Momenta Pharmaceuticals, Inc. Compositions and methods for treating hemolytic disease of the fetus and newborn
WO2025004683A1 (ja) * 2023-06-30 2025-01-02 国立大学法人大阪大学 がん検査方法及びがん治療剤
TW202521576A (zh) 2023-07-30 2025-06-01 美商健生生物科技公司 結合至突變型鈣網蛋白之分子及其用途
TW202527982A (zh) 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
WO2025109518A1 (en) 2023-11-21 2025-05-30 Janssen Biotech, Inc. Methods for treatment of myeloproliferative neoplasms
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
WO2025186787A1 (en) 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
WO1994002610A1 (en) * 1992-07-17 1994-02-03 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
FR2706486B1 (fr) * 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
WO2001006989A2 (en) 1999-07-27 2001-02-01 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
US6277974B1 (en) * 1999-12-14 2001-08-21 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
DE10019157A1 (de) 2000-04-18 2001-11-15 Stefan Duebel Verfahren zum Einbringen von Liganden in lebende Zellen
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US20040052762A1 (en) * 2001-09-10 2004-03-18 Hua Yu Stat3 agonists and antagonists and therapeutic uses thereof
EP1353937A4 (en) * 2000-12-29 2005-04-13 Savient Pharmaceuticals Inc SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY
AU2003219277A1 (en) * 2002-03-14 2003-09-29 Medical Research Council Intracellular antibodies
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
HUE026914T2 (en) * 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
JP2006519763A (ja) 2002-11-08 2006-08-31 アブリンクス エン．ヴェー． 治療用ポリペプチドの投与法およびそのためのポリペプチド
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
AU2003286002B2 (en) * 2002-11-08 2011-06-16 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
GB0226729D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
WO2005052002A2 (en) 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
EP2949668B1 (en) 2005-05-18 2019-08-14 Ablynx N.V. Improved nanobodies tm against tumor necrosis factor-alpha
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
US20100143371A1 (en) * 2006-10-31 2010-06-10 Zhenping Zhu Intrabodies
CA2588106A1 (en) * 2007-05-18 2008-11-18 Nrc - Institute For Biological Sciences Single-domain antibodies and heavy chain antibody against egfr and uses thereof
EP2008666A1 (en) 2007-06-29 2008-12-31 Institut Pasteur Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications
US20110195509A1 (en) 2007-09-06 2011-08-11 Drew Pardoll Treatment of th17-mediated autoimmune disease via inhibition of stat 3
WO2010001325A2 (en) * 2008-06-30 2010-01-07 Silenseed Ltd Methods, compositions and systems for local delivery of drugs
EP2143735A1 (en) * 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
US20130177979A1 (en) 2010-06-22 2013-07-11 University Of Central Florida Research Foundation, Inc. Methods and compositions for cell permeable stat3 inhibitor
US9879093B2 (en) * 2011-12-20 2018-01-30 Adaerata, Limited Partnershp Single domain antibodies as inhibitors of PCSK9
EP2920308B1 (en) * 2012-10-31 2018-12-12 Ionis Pharmaceuticals, Inc. Cancer treatment
EP2970392B1 (en) * 2013-03-15 2019-07-10 Dana-Farber Cancer Institute, Inc. Stabilized sos1 peptides
US9802888B2 (en) * 2013-03-22 2017-10-31 University Of Hawaii STAT3 inhibitors
CN103368197B (zh) 2013-07-15 2015-11-25 国家电网公司 模块化多电平换流器的阀基控制设备和方法
SG11201601443PA (en) 2013-08-29 2016-03-30 Hope City Cell penetrating conjugates and methods of use thereof
EP2873680A1 (en) 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Oligopeptide and methods for producing conjugates thereof
EP2899208A1 (en) 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
HUE047601T2 (hu) 2014-10-23 2020-05-28 Singh Molecular Medicine Llc Intracelluláris antigének ellen irányuló egyetlen domén antitestek

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof

Also Published As

Publication number Publication date
KR20170070002A (ko) 2017-06-21
WO2016065323A2 (en) 2016-04-28
IL250961A0 (en) 2017-04-30
CY1122035T1 (el) 2020-10-14
IL289769B1 (en) 2024-01-01
AU2022204167A1 (en) 2022-06-30
AU2015335600A1 (en) 2017-03-16
JP2017538671A (ja) 2017-12-28
ES2731876T3 (es) 2019-11-19
EP3209685A4 (en) 2018-01-24
BR122020006914B1 (pt) 2022-03-22
JP6928773B2 (ja) 2021-09-01
KR20190108646A (ko) 2019-09-24
PT3590962T (pt) 2021-12-15
SMT201900413T1 (it) 2019-09-09
RS62694B1 (sr) 2022-01-31
SMT202100695T1 (it) 2022-01-10
AU2019204614B2 (en) 2020-10-22
MX379450B (es) 2025-03-11
JP2021165278A (ja) 2021-10-14
JP6670963B2 (ja) 2020-03-25
HUE047601T2 (hu) 2020-05-28
EP3209685A2 (en) 2017-08-30
HUE057605T2 (hu) 2022-06-28
US20160115244A1 (en) 2016-04-28
KR102023289B1 (ko) 2019-09-19
TWI664289B (zh) 2019-07-01
LT3590962T (lt) 2021-12-27
TW201615834A (zh) 2016-05-01
LT3209685T (lt) 2019-08-26
US20160115226A1 (en) 2016-04-28
JP2022037002A (ja) 2022-03-08
SI3209685T1 (sl) 2019-10-30
HRP20191056T1 (hr) 2019-09-20
US20160115248A1 (en) 2016-04-28
IL289769A (en) 2022-03-01
EP4006052A1 (en) 2022-06-01
MX2017003268A (es) 2017-08-02
US9546211B2 (en) 2017-01-17
ES2900253T3 (es) 2022-03-16
RS59063B1 (sr) 2019-08-30
US9663570B2 (en) 2017-05-30
DK3209685T3 (da) 2019-07-29
KR20180021205A (ko) 2018-02-28
CA2962275A1 (en) 2016-04-28
KR20190107199A (ko) 2019-09-18
AU2019204614A1 (en) 2019-07-18
CN111848793B (zh) 2023-08-18
BR122020006914B8 (pt) 2023-01-31
PT3209685T (pt) 2019-06-27
KR102207381B1 (ko) 2021-01-27
JP7195400B2 (ja) 2022-12-23
AU2015335600B2 (en) 2019-04-04
CA3052777A1 (en) 2016-04-28
EP3590962A1 (en) 2020-01-08
JP2020015732A (ja) 2020-01-30
AU2021200416B2 (en) 2022-06-09
BR112017008165A2 (pt) 2018-03-06
JP2019142885A (ja) 2019-08-29
CN106852148B (zh) 2020-07-31
PL3209685T3 (pl) 2020-01-31
SI3590962T1 (sl) 2022-02-28
BR112017008165B8 (pt) 2020-10-27
CY1124867T1 (el) 2022-11-25
CA2962275C (en) 2019-11-05
BR122020006907B8 (pt) 2023-01-31
BR122020006907B1 (pt) 2022-03-22
IL289769B2 (en) 2024-05-01
CN106852148A (zh) 2017-06-13
CN111848793A (zh) 2020-10-30
MX2021001098A (es) 2021-03-31
EP3209685B1 (en) 2019-04-24
BR112017008165B1 (pt) 2020-04-22
RU2017116710A (ru) 2018-11-23
US9695234B2 (en) 2017-07-04
AU2021200416A1 (en) 2021-02-25
KR102207382B1 (ko) 2021-01-27
BR122020006918B8 (pt) 2023-01-31
BR122020006918B1 (pt) 2022-03-15
CA3052777C (en) 2021-06-01
HRP20211889T1 (hr) 2022-03-04
US20160115247A1 (en) 2016-04-28
WO2016065323A3 (en) 2016-06-16
EP3590962B1 (en) 2021-09-29
DK3590962T3 (da) 2021-12-13
PL3590962T3 (pl) 2022-01-31
CA3114318A1 (en) 2016-04-28
IL250961B (en) 2022-02-01
JP6986180B2 (ja) 2021-12-22

Similar Documents

Publication Publication Date Title
KR101831123B1 (ko) 세포내 항원에 대해 지향된 단일 도메인 항체
RU2810002C2 (ru) Однодоменные антитела, направленные против внутриклеточных антигенов
US9850321B2 (en) Single domain antibodies directed against intracellular antigens

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170309

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170726

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20170726

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20171113

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180213

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180214

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180219

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20210201

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20220128

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20230201

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240125

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20250204

Start annual number: 8

End annual number: 8